Pregnancy is a delicate journey, and for women with Type 1 diabetes, it can be even more challenging. But here's a groundbreaking discovery: Automated insulin delivery systems are revolutionizing glucose control for these expectant mothers!
An international research team, with University of Calgary researchers at the helm, has unveiled a game-changer. Their study reveals that automated insulin delivery (AID) technology significantly enhances glucose management during pregnancy for Type 1 diabetes patients. This is crucial, as maintaining healthy glucose levels is essential for both the mother and the baby's well-being.
The AID system acts like a healthy pancreas, automatically adjusting insulin doses through a pump in real-time, based on current and predicted glucose readings. Dr. Lois Donovan, an endocrinologist and researcher, highlights the importance of this control, especially during pregnancy.
In a multicenter clinical trial published in JAMA, researchers compared a hybrid closed-loop (HCL) AID system with traditional insulin injections or non-automated pumps, along with continuous glucose monitoring. Dr. Denice Feig, the other co-principal investigator, emphasizes the difficulty of managing glucose levels during pregnancy, even with dedicated care.
Pregnancy with Type 1 diabetes comes with risks, including higher chances of miscarriage, preeclampsia, and other health issues. Newborns are often affected, with increased risks of being born large or premature, having low blood glucose, and facing birth defects.
But the study's findings are promising. The AID system extended the time spent in the desired glucose range by three hours daily compared to standard methods. This is significant, as every 72 minutes of additional time in the target range is linked to reduced newborn complications, according to larger studies.
The AID system, Tandem t:slim X2 insulin pump with Control-IQ technology, has shown its potential. And this is the part most people miss: AID systems have already proven effective in non-pregnant Type 1 diabetes patients, but their use in pregnancy was less explored. Most AIDs weren't designed for the precise glucose control needed during pregnancy or to adapt to the rapidly changing insulin needs.
The study's results were consistent across all 14 sites in Canada and Australia. Participants using the AID maintained healthier glucose levels, spending less time above or below the target range. This improvement was immediate and sustained throughout pregnancy.
Dr. Feig believes these findings will empower pregnant women and those planning pregnancy to consider AID systems, potentially leading to better glucose management and pregnancy outcomes.
The research was a collaborative effort, with the University of Calgary leading and clinics in Calgary, Toronto, Vancouver, Quebec City, London (Ont.), Winnipeg, Halifax, Canberra, Melbourne, and Sydney participating. Funding was provided by various organizations, including Diabetes Canada, MSI Foundation, and the University of Calgary Clinical Research Fund, with in-kind support from Dexcom Canada, Tandem Diabetes Care, and RxFood.
But here's where it gets controversial: Should AID systems be adapted specifically for pregnancy, given the unique challenges and risks? Or is the current technology sufficient? Share your thoughts in the comments, and let's explore the possibilities together.
